Humphries Romney M, Yang Shangxin, Hemarajata Peera, Ward Kevin W, Hindler Janet A, Miller Shelley A, Gregson Aric
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7. doi: 10.1128/AAC.01165-15. Epub 2015 Jul 20.
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.
头孢他啶-阿维巴坦是美国食品药品监督管理局（FDA）批准用于治疗耐碳青霉烯类肠杆菌科细菌的首个抗菌药物。阿维巴坦是一种非β-内酰胺类β-内酰胺酶抑制剂，可使包括肺炎克雷伯菌碳青霉烯酶（KPC）在内的A类丝氨酸碳青霉烯酶失活。我们报告了1株产KPC的肺炎克雷伯菌分离株，该菌株对头孢他啶-阿维巴坦耐药（MIC为32/4 μg/ml），分离自1例既往未接受过头孢他啶-阿维巴坦治疗的患者。
